David Broecker to Step Aside as IBRI CEO

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

The Indiana Biosciences Research Institute in Indianapolis has named its next chief executive officer. Rainer Fischer, who will continue to serve as chief scientific and innovation officer, will succeed David Broecker (pictured) as CEO October 1. Broecker, the IBRI’s founding CEO, will stay on as an advisor to the institute. Fischer came to the IBRI last year from the Fraunhofer Institute for Molecular Biology and Applied Ecology in Germany. He helped expand employment at the institute from 40 to 680 and led a team that raised nearly one billion Euro in outside research funding. His experience also includes co-founding five startups in the biotech space. Fischer has published over 500 scientific papers, holds 40 patents and has 64 patents pending.

During Broecker’s time at the IBRI, more than $120 million in funding has been raised and partnerships with the likes of Dow AgroSciences, Eli Lily and Co., Roche Diagnostics and the Indiana Clinical and Translational Science Institute have been secured.